BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsEarnings

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 20, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.

Open original release

Related news

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-01-20 21:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

APLSApellis Pharmaceuticals2026-02-24 12:05 EST

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-02-10 12:00 EST

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

KRYSKrystal Biotech2026-07-23 21:00 EST

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

View all latest news

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is an RNA-interference company with deep programs in liver, pulmonary, and rare disease targets.

Recent company news

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-06-22 16:33 EST

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

ARWRArrowhead Pharmaceuticals2026-06-18 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Stock data

Close
85.53 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States